CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
800.92MUSDvs all stocks (USD)
Revenue (TTM)
41.47MUSDvs all stocks (USD)
Profit Margin
-147.38%vs Biotechnology peers
Beta
1.03xvs all stocks
52-Week Change
29.50%vs all stocks
Market Capitalization
800.92MUSDvs all stocks (USD)
Enterprise Value
667.33MUSDvs all stocks (USD)
Forward P/E
-9.42xvs Biotechnology peers
Price to Sales (TTM)
19.26xvs Biotechnology peers
Price to Book (MRQ)
4.58xvs Biotechnology peers
Enterprise to Revenue
16.09xvs Biotechnology peers
Enterprise to EBITDA
-12.35xvs Biotechnology peers
Gross Margin
94.36%vs Biotechnology peers
Profit Margin
-147.38%vs Biotechnology peers
Operating Margin
-3835.26%vs Biotechnology peers
Return on Assets (TTM)
-14.32%vs Biotechnology peers
Return on Equity (TTM)
-40.21%vs Biotechnology peers
Revenue (TTM)
41.47MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1060USDUpdated Sep 28, 2026Quarterly Revenue Growth
-97.60%vs Biotechnology peers
Gross Profit (TTM)
35.67MUSDvs all stocks (USD)
EBITDA (TTM)
-54.02MUSDvs all stocks (USD)
Net Income (TTM)
-61.12MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-97.60%vs Biotechnology peers
Operating Cash Flow (TTM)
-64.99MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-44.77MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
49.80MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
274.00KUSDFY2025 · Dec 31, 2025Gross Profit
49.53MUSDFY2025 · Dec 31, 2025Operating Income
-48.91MUSDvs all stocks (USD)
Pre-tax Income
-50.34MUSDFY2025 · Dec 31, 2025Net Income
-50.34MUSDFY2025 · Dec 31, 2025EBIT
-42.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-41.38MUSDFY2025 · Dec 31, 2025Research & Development
61.12MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
37.32MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.91MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
8.34MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-50.34MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-65.67MUSDFY2025 · Dec 31, 2025Free Cash Flow
-65.67MUSDDerived from operating cash flow minus capital expenditure. This filing charges 621K of depreciation against 0 of capital expenditure, and its own free-cash-flow line reads -67.85M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
63.33MUSDFY2025 · Dec 31, 2025Interest Paid
8.33MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-50.34MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
621.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.52MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-42.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.09MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-30.22MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
707.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-139.84MUSDFY2025 · Dec 31, 2025Sale of Investments
252.86MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
113.02MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-48.00MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-572.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-48.57MUSDFY2025 · Dec 31, 2025Shares Outstanding
444.94MSharesUpdated Sep 28, 2026Float Shares
218.99MSharesUpdated Sep 28, 2026Shares Short
28.79MSharesUpdated Sep 28, 2026Short Ratio
11.30daysvs all stocks
Short % of Shares Outstanding
12.19%vs all stocks
% Held by Insiders
1.12%vs all stocks
% Held by Institutions
83.80%vs all stocks
Total Cash (MRQ)
190.61MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.4280USDUpdated Sep 28, 2026Total Debt (MRQ)
59.24MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3394xvs Biotechnology peers
Current Ratio (MRQ)
13.37xvs Biotechnology peers
Book Value per Share (MRQ)
0.3920USDUpdated Sep 28, 2026Total Assets
184.99MUSDvs all stocks (USD)
Total Current Assets
101.89MUSDFY2025 · Dec 31, 2025Total Liabilities
77.45MUSDFY2025 · Dec 31, 2025Total Non-current Assets
83.09MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
56.58MUSDFY2025 · Dec 31, 2025Total Current Liabilities
20.87MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
34.33MUSDFY2025 · Dec 31, 2025Other Short-term Investments
61.90MUSDFY2025 · Dec 31, 2025Accounts Receivable
2.38MUSDFY2025 · Dec 31, 2025Inventory
281.00KUSDFY2025 · Dec 31, 2025Accounts Payable
3.08MUSDFY2025 · Dec 31, 2025Short-term Debt
6.24MUSDFY2025 · Dec 31, 2025Long-term Debt
56.58MUSDFY2025 · Dec 31, 2025Common Stock (Book)
366.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.02BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
107.54MUSDvs all stocks (USD)
Treasury Stock
5.19MUSDFY2025 · Dec 31, 202552-Week Low
1.10USDUpdated Sep 28, 202652-Week High
2.68USDUpdated Sep 28, 202652-Week Change
29.50%vs all stocks
Beta
1.03xvs all stocks
50-Day MA
2.25USDUpdated Sep 28, 2026200-Day MA
1.83USDUpdated Sep 28, 2026Avg 10-Day Volume
3.41MSharesUpdated Sep 28, 2026Avg 30-Day Volume
2.84MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.1600USDUpdated Sep 28, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 19.26Revenue Growth YoY: -0.98
High gross margins eroded by operating costsNotable
Gross Margin: 0.94Profit Margin: -1.47
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jacobio Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
4D Molecular Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
HK inno.N Corporation
Tier 1ProductionApproval-Gated PipelineRule
Beijing Chunlizhengda Medical Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
DNA Link Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Geron Corporation
Tier 1ProductionApproval-Gated PipelineRule
Chengda Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanxi Zhendong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule